|
MyungMoon Pharm. Co., Ltd.
Well-known for its signature antiemetic “Kimite” patch at home and abroad, MyungMoon Pharm. Co. is a Korea-based company engaged in the manufacturing and distribution of highquality pharmaceuticals for the past 27 years, and it has achieved remarkable growth via constant research and development.
Since it was established in 1983 based on its founding principles - Advancement, Harmony, and Creation - the company has developed and provided its clients with quality pharmaceuticals by conducting consistent and extensive research and development endeavors. One of the company’s recent achievements was the introduction of the transdermal therapeutic system, under which MyungMoon Pharm. came up with a new galenical form called PATCH, as the first company to do so in Korea.
Headquartered in Dogok-dong, Seoul and with its production facilities in Hyangnam-Myun Industrial Complex in Gyeonggi-do, MyungMoon Pharm. provides both ethical (ETC) drugs and over the counter (OTC) drugs. Its ETC drugs include anesthetic agents, digestive system drugs, muscle relaxants, antiphlogistic agents, respiratory system drugs, antibiotics, circulatory drugs, hormone agents, calcium, narcotics and drugs for dermatology systems. Its OTC drugs include antinauseant agents, antifungal agents, antitussive drugs, hepatics, digestive system drugs, antiallergic agents, immunologic agents, calcium, muscle relaxants, probiotic agents, total cold drugs and parasiticides.
The growth of MyungMoon Pharm. was based on OTC drugs, including its signature antiemetic “Kimite” patch that has become synonymous with antiemetics among Korean consumers, and export markets are being expanded. It is now increasingly turning its eyes to higher-value-added specialized medicines, especially anti-depressant, antihypertensive, arthritic drugs and dementia drugs. The company expects these medicines to account for about 60% of the total production for the next four years.
Moreover, the company, which went public on the KOSPI in 2008 estimates that about 90% of the company’s sale revenues come from the ETC drugs, including its main items such as arthritic drugs and anesthetics. The sales jumped by a significant 28% for the past two years. MyungMoon Pharm. will continue to exert its efforts toward improving national health and welfare through continuous research and development of the most advanced medicines.
|
Other Articles
